GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (FRA:S1K) » Definitions » Cyclically Adjusted PB Ratio

Predictive Oncology (FRA:S1K) Cyclically Adjusted PB Ratio : (As of Jun. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Predictive Oncology Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Predictive Oncology Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Predictive Oncology's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Cyclically Adjusted PB Ratio Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Predictive Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Predictive Oncology's Cyclically Adjusted PB Ratio

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Cyclically Adjusted PB Ratio falls into.



Predictive Oncology Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Predictive Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Predictive Oncology's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.925/131.7762*131.7762
=0.925

Current CPI (Mar. 2024) = 131.7762.

Predictive Oncology Quarterly Data

Book Value per Share CPI Adj_Book
201406 -4,022.034 100.560 -5,270.595
201409 -4,960.000 100.428 -6,508.257
201412 -7,214.516 99.070 -9,596.289
201503 -8,133.333 99.621 -10,758.561
201506 -8,293.939 100.684 -10,855.199
201509 4,964.423 100.392 6,516.416
201512 3,614.423 99.792 4,772.858
201603 212.864 100.470 279.191
201606 44.916 101.688 58.206
201609 0.588 101.861 0.761
201612 38.344 101.863 49.604
201703 114.730 102.862 146.980
201706 91.955 103.349 117.248
201709 61.425 104.136 77.729
201712 65.351 104.011 82.796
201803 71.654 105.290 89.679
201806 47.593 106.317 58.990
201809 38.707 106.507 47.891
201812 0.653 105.998 0.812
201903 0.703 107.251 0.864
201906 127.178 108.070 155.076
201909 119.214 108.329 145.017
201912 49.677 108.420 60.379
202003 31.911 108.902 38.614
202006 15.740 108.767 19.070
202009 12.521 109.815 15.025
202012 2.193 109.897 2.630
202103 12.238 111.754 14.431
202106 13.488 114.631 15.505
202109 12.410 115.734 14.130
202112 10.862 117.630 12.168
202203 10.244 121.301 11.129
202206 8.118 125.017 8.557
202209 7.624 125.227 8.023
202212 5.217 125.222 5.490
202303 4.364 127.348 4.516
202306 3.388 128.729 3.468
202309 2.706 129.860 2.746
202312 1.880 129.419 1.914
202403 0.925 131.776 0.925

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Predictive Oncology  (FRA:S1K) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Predictive Oncology Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology (FRA:S1K) Business Description

Traded in Other Exchanges
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

Predictive Oncology (FRA:S1K) Headlines

No Headlines